|
Method of increasing levomycetinum (chloramphenicol) efficiency 5 g of levomycetinum are dissolved in 100 ml of distilled water, activated with silver ions in concentration 1.0 mg in 100 ml, first polymerisation of levomycetin solution with glutaraldehyde is carried out at 40°C for 2-3 days, after which second polymerisation of levomycetin solution is carried out with 0.2-0.3% of etonium at 40°C for 2-3 days, with content of glutaraldehyde and etonium in 100 ml of solution constituting 0.1% and 0.2-0.3% respectively. |
|
Differential diagnostic technique and therapeutic approach to night eating syndrome Differential therapy is conducted depending on the number of night meals per a week. Sertraline in a dose of 100 mg is prescribed to the patients having two or less night meals per a week after going to bed and referred to a group of those with primarily evening manifestations of night eating syndrome. Agomelatine in a dose of 25 mg a day is prescribed to the patients having three or more night meals after going to bed and referred to a group of those with primarily night manifestations of night eating syndrome. The treatment continues until stable remission is achieved and further for 6 months. |
|
|
Suspensions of nanoparticles, containing carboxyvinyl polymer Ophthalmological composition of water-based suspension for local application contains caboxylvinyl polymer in concentration from 0.1 to 0.5% (wt/vol), galactomannan in concentration from 0.1 to 0.4% (wt/vol), borate in concentration from 0.4 to 2.0% (wt/vol) and sparingly soluble compound in form of particles, representing nepafenacum in concentration from 0.25 to 0.35% (wt/vol). Said compound possesses water solubility at 25°C from 0.001 to 0.1% (wt/vol) and particle size from 50 to 70 nm. |
|
Invention refers to compounds of formula (1) or their pharmaceutically acceptable salts, wherein in formula (1) R1 means a linear or branched C1-C8 alkyl group, phenyl or benzyl; R2 means hydrogen or C1-C8 alkyl-2-formamide acetate group; R3 means acyl group of carboxylic acid specified in groups of 2,6-dichlorbenzoic or 2,6-di(trifluormethyl)benzoic acid. The invention also refers to using the compounds of formula (1) and a pharmaceutical composition containing them. |
|
Invention refers to medicine, particularly to cardiology, and is applicable for the left ventricular hypertrophy (LVH) correction in elderly and senile patients with arterial hypertension. When developing the method presented as the invention, the conducted research has included 80 patients with arterial hypertension and the high risk of cardiovascular complications (23 males and 57 females) aged from 60 to 85 years (average age of 72.4±6.5 years, a median of 72 years, quartiles of 69.5 and 76 years). The duration of the disease has made 19.6±6.8 years. All the patients have undergone echocardiographic examination before treatment and 6 months later with underlying combination antihypertensive therapy. The patients have been randomised into three groups: the patients from the first group have been taking a combination of ACE inhibitors with a diuretic (perindopril 5 mg and indapamide 1.25 mg); the patients from the second group have been taking a fixed combination of ACE inhibitors and a calcium antagonist (lisinopril 5 mg and amlodipine 10 mg); the third group of patients was a reference one, which has been taking another antihypertensive therapy. |
|
Method of treating patients with chronic endometritis and tubal and peritoneal infertility factor Method involves antibacterial, antimycotic, antiviral therapy taking into account sensitivity and recovered pathogenic flora and/or immune-enhancing therapy. From the 3rd day of the above therapy, local treatment involving the intrauterine insertion of a device for administering a complex of preparations and the prescribed hormone therapy is conducted. The device for administering the complex of preparations is presented by the Foley catheter, which is used to administer Miramistin 5 ml daily, Cefazoline or Ceftriaxone 4-6 minutes later, then Derinate 5 ml 4-6 minutes on even days, Longidaza 3 thousand units on odd days; the procedure is immediately followed by inserting a Miramistin tampon vaginally for 1-2 hours; one capsule of Polygynax is inserted vaginally for the night, whereas the hormone therapy is prescribed after the treatment. |
|
|
Method of treating fibromyalgia syndrome Group of inventions refers to medicine and aims at treating fibromyalgia syndrome. The method of treating fibromyalgia syndrome involves administering a therapeutically effective amount of a substance having structural formula , or its pharmaceutically acceptable salt into a mammal in need thereof, wherein Rx, R1 and R2 represent hydrogen and x is equal to 1. What is also provided is a pharmaceutical composition containing the substance having structural formula (1), or its pharmaceutically acceptable salt. |
|
Method of treating attention deficit/hyperactivity syndrome Group of inventions refers to medicine and aims at treating attention deficit/hyperactivity syndrome (ADHD). The method of treating attention deficit/hyperactivity syndrome involves administering a therapeutically effective amount of a compound having formula , or its pharmaceutically acceptable salt into a mammal in need thereof, wherein R, R1 and R2 mean hydrogen and x=1. What is also provided is a pharmaceutical composition containing a compound having formula (1), or its pharmaceutically acceptable salt. |
|
Invention relates to medicine, namely to ophthalmology, and can be used for the treatment of a primary open-angle cataract at the background of pseudoexfoliation syndrome in a combination with the cataract. Normalisation of the intra-ocular pressure is carried out by the instillation of b-adrenoblockers and/or carboanhydrase inhibitors. Selective laser trabeculoplasty is performed. Phacoemulsification of the cataract with the implantation of an intraocular lens is performed to the patient the following day after exposure to laser. In the course of performing the phacoemulsification of the cataract washing out pseudoexfoliative particles and pigment granules from the angle of the anterior eye chamber is realised. |
|
|
Method for combined prolonged anaesthesia assisting hip replacement Dexamethasone 8 mg and ketoprofen 100 mg is administered intravenously once prior to the operation. A lumbar plexus is blocked in a combination with a parasacral block and inserting perineural catheters to administer weak 0.2% Ropivacaine, local anaesthetic 20 ml. Paracetamol 1,000 mg is administered intravenously 30 minute before the operation is completed. After the operation is completed, the perineural catheter of the lumbar plexus is used to infuse 0.2% Ropivacaine 300 ml at 6-8 ml/hour for 4-5 days. Ketoprofen 100 mg is administered intramuscularly twice a day for 3 days. Through the perineural catheter of the parasacral plexus, 0.2% Ropivacaine 10 ml is administered twice every 12 hours. |
|
|
Anti-inflammatory antibacterial wound-healing agent Invention represents an anti-inflammatory antibacterial wound-healing agent containing a polyethylene oxide base with molecular weight 400 (PEO-400) as a forming agent, as well as polyethylene oxide with molecular weight 1,500 (PEO-1500); an active substance is chloramphenicol and methyluracil; the agent is characterised by the fact that it additionally contains rifampicin and/or cycloserine; the cycloserine content in the rifampicin mixture is specified within the range of 18 to 82 wt %, whereas the ingredients are taken in certain ratio, wt %. |
|
|
Agent for pyoinflammatory processes in soft tissues and mucous membranes Therapeutic agent contains carboxymethyl cellulose sodium salt as a base and a combination of antiseptic, 0.01% Myramistinum and metronidazole as therapeutic ingredients. The invention provides preparing the therapeutic agent possessing the antiseptic, wound-healing and sorption action on local pyoinflammatory processes in soft tissues and mucous membranes, used in surgery, dermatology, obstetrics and gynaecology, otorhinolaryngology. |
|
Method for correction of night eating syndrome in patients with anxiety and depressive disorders Correcting night eating syndrome in the patients with anxiety and depressive disorders is ensured by prescribing agomelatine 25mg a day for the night. The therapeutic course is continued until a long-lasting remission is observed for 6 months and more. |
|
|
Sulfogel-preparation for treatment of infected wounds in toe region of animals and method of its use Preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface. |
|
![Pharmaceutical depot, containing n-{ 5-[(cyclopropylamino)carbonyl]-2-methylphenyl} -3-fluoro-4-([pyridin-2-ylmethoxy)benzamide](http://img.russianpatents.com/img_data/1191/11913104-s.jpg)
|
Invention relates to field of pharmaceutics and represents pharmaceutical depot, made for introduction by intra-articular injection into joint of subject, suffering from osteoarthritis, which contains microparticles or nanoparticles, composed of N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-[pyridin-2-ylmethoxy)benzamide or its pharmaceutically acceptable salt and biodegradable copolymer lactic acid-glycolic acid. |
|
Amine derivatives and their use for treatment of ophthalmological diseases and illnesses Invention relates to new amine derivatives of the following structural formula: |
|
Galenical preparations of organic compounds Claim describes a standard solid dosage form for oral administration which represents a mini-tablet having a core and an outer coating, wherein the core contains a therapeutically effective amount of aliskiren or its pharmaceutically acceptable salt, while the outer coating represents a film coating containing a taste masking material specified in polyacrylates, and/or a release modifying ingredient of the coating specified in cellulose derivatives and acryl copolymers, and a mixture thereof. The above mini-tablet has a size of 1 mm to 4 mm and contains aliskiren in an amount making 2 mg/tablet to 4 mg/tablet. The oral solid dosage form is preferentially applied in paediatrics. |
|
Invention relates to medicine, namely to pharmacology, and deals with a synthetic biologically active compound - hydrochloride of 2-(diethylamino)ethyl ether of 9-hydroxy-9H-fluorene carboxylic acid, representing an amyzilum M-cholinoblocker derivative. The said amyzilum derivative has not been described before. The claimed compound possesses low toxicity, its synthesis is simple and available. It is demonstrated that hydrochloride of 2-(diethylamino)ethyl ether of 9-hydroxy-9H-fluorene carboxylic acid, representing the amyzilum M-cholinoblocker derivative demonstrates an expressed antidepressant activity and an anxiolytic action, possesses a sedative, and in high doses a soporific effect, it also positively influences an exploratory ability and memory. In addition, it has been stated that the claimed pharmacological substance in expressiveness of the antidepressant properties surpasses the widely applied tricyclic antidepressant amitriptylinum. The obtained data make it possible to recommend the claimed amyzilum derivative as the antidepressant for the treatment of depression and anxiety disorders. |
|
Method for preparation of patient for glaucoma surgery 1-1.5 hours before the surgery, the selective β-adrenergic blocker Betaloc is injected in an amount of 0.3-0.5 ml subconjunctivally in an upper semi-circle of the eyeball in accordance with 10 to 2 o'clock of a clock face. Then, 30-40 minutes before the surgery, 50% analgin 2.0 ml, 1% dimedrol 1.0 ml, seduxen 2.0 ml are injected intramuscularly. The surgery is immediately preceded by a subtenon block with 2% naropin 1.5 ml. |
|
|
Method for preperitoneal block following median postoperative ventral hernioplasty Invention refers to medicine, namely to abdominal surgery and anaesthesiology, and can be used where it is necessary to anaesthetise after the prosthetic hernioplasty for median postoperative ventral hernias. That is ensured by placing an endoprosthesis under the aponeurosis, a polyvinylchloride catheter is placed into the formed spaced around the periphery of a postoperative wound in the form of an oval above the endoprosthesis plane at 2.5-3 cm from its edges. Along its full length, the catheter has multiple side holes. Single openings are created in a projection of a lower corner of the wound, and the catheter ends are brought out onto the skin. An inlet of the catheter is attached to a local anaesthetic dosage device by means of a cannula. That is followed by a controlled prolonged irrigation with 2.5% Ropivacaine 20 ml every 6-8 hours during 2-3 days. |
|
Method for providing higher efficacy and safety of ultrafast opioid detoxification What is involved is infusion therapy with crystalloid solutions at 15 ml/kg of a patient's body weight. That is followed by puncturing and catheterising an epidural space at the level of ThVII-ThVIII according to the standard practice and introducing a test dose of 2% lidocaine 3 ml. If observing no signs of intrathecal introduction of local anaesthetics 10 minutes later, a basic dose containing 0.75-1% naropin 10 ml or 0.25-0.5% marcaine 10 ml and clofelin 3-5 mcg/kg is introduced. Total intravenous anaesthesia follows 20 minutes after pre-medication with atropine 0.01 mg/kg, 1% diphenylhydramine 1 ml and relanium 10 mg and urethral catheterisation. A narcosis is induced with propofol in a dose of 2 mg/kg. Anaesthesia is maintained with propofol 2-4 mg/kg·h. After that, within the first hour following the detoxification, naloxone 12 mg is introduced intravenously; a naloxone measurement rate is supposed to make 0.8 mg/h for 4-5 following hours of general anaesthesia. The repeated introduction of 0.75-1% naropin 6 ml or 0.25-0.5% marcaine 6 ml and clofelin 2-3 mcg/kg into the epidural space is performed 90 minutes later. After the procedure is terminated, and the patient recovers, prolonged epidural analgesia is conducted by introducing 0.2% naropin 10 ml and clofelin 1 mcg/kg into the epidural space every 4 hours for 24-48 hours. |
|
|
Fatty acid derivatives for oral administration providing improved taste qualities Invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, having physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterise butyrate. |
|
Method of treating polycystic kidney diseases by ceramide derivatives Invention relates to the field of pharmaceutics and medicine and deals with medication for treatment of polycystic kidney disease, which represents a compound of general formula (1), as well as a method of treating polycystic kidney disease by introduction of efficient amount of the compound of general formula (1) to a patient who requires it. |
|
Preparation comprises glucose, sodium chloride, sodium carbonate and potassium chloride, calcium acetate or calcium lactate, ascorbic acid, iron sulfate, chloromycetin and phtalazol with the following ratio of the components, g/l aqueous solution: glucose - 30.0; sodium chloride - 9.0; sodium carbonate - 5.0; potassium chloride - 0.2; calcium acetate or calcium lactate - 1.0; ascorbic acid - 0.5; iron sulfate - 0.2; chloromycetin - 1.0; phtalazol - 1.0. |
|
|
Derivatives of aminoalkanols, method of obtaining aminoalkanols and their application Invention relates to novel derivatives of aminoalkanols, which can be used for manufacturing medication, applied in prevention, prophylaxis and/or treatment of diseases or symptoms of neurological origin, in particular epilepsy. Said compounds are selected from R,S-2N-[(2-chloro-6-methylphenoxy)ethyl]amino-1-butanol, R,S-2N-[(2-chloro-6-methylphenoxy)ethyl]amino-1-butanol hydrochloride, R-(-)-2N-[(2-chloro-6-methylphenoxy)ethyl]amino-1-butanol, R-(-)-2N-[(2-chloro-6-methylphenoxy)ethyl]amino-1-butanol hydrochloride, S-(+)-2N-[(2-chloro-6-methylphenoxy)ethyl]amino-1-butanol, R,S-2N-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol, R-(+)-2N-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol, S-(-)-2N-[(2,6-dimethylphenoxy)acetyl]amino-1-propanol, R,S-1N-[(2-chloro-6-methylphenoxy)acetyl]amino-2-butanol. Invention also relates to method of obtaining claimed compounds. |
|
Method for preparing combined antibacterial preparation for treating acute intestinal infections Invention refers to medicine and biotechnology, and represents a method for preparing a combined antibacterial preparation for treating acute intestinal infections. The invention is to prepare a biological ingredient biomass representing a complex of immunoglobulins or bifidus bacteria biomass, to mix it with an antibiotic substance in specified proportions, and differs from the known analogues by the fact that mixing the two ingredients of the preparation is preceded by grinding the biological ingredient only to be ground to the greatest maximum bulk density of the ground material. |
|
|
Antiseptic drug with haemostatic action, and method for preparing it Invention refers to an antiseptic drug with haemostatic action for wound cleaning. The drug contains ingredients in the following ratio, wt %: an antimicrobial substance - 0.01-3, an active complex - 1-25, glycerol - 2-35 and water - up to 100. The antimicrobial substance is specified in a group consisting of cetyl pyridinium or cetyl methyl ammonium halogenide, chlorhexidine, miramistin and other quaternary bases applicable in medical practice to treat burns and to clean open wounds, and the active complex is presented by a haemostatic preparation in the form of a mixed-ligand chelated complex of zinc, ethylene diamine tetraacetic acid and ε - aminocapronic acid. The invention also refers to a method for preparing the antiseptic drug with haemostatic action. The method consists in the fact the active complex is prepared in a water-glycerol mixture while stirring by dissolving ε - aminocapronic acid, then zinc oxide, adding powdered ethylene diamine tetraacetic acid and after dissolved completely, adding a liquid solution of the antimicrobial substance in the water-glycerol mixture. |
|
|
Combined antibacterial preparation for treating acute intestinal infections Invention refers to an antibacterial preparation for treating gastrointestinal diseases, preferentially acute intestinal infections, including unexplained. The declared preparation represents a mixture of an antibiotic and a biological ingredient, wherein the antibiotic is presented by chloramphenicol, while the biological ingredient is a complex of immunoglobulins IgG(56-60):IgA(16-22):IgM(22-24) in the following ratio, mg/capsule: chloramphenicol - 300 mg, the complex of immunoglobulins IgG,IgA,IgM - 120 mg. |
|
Method for preparing laevomycetin ointment with glutaric aldehyde and aethonium Invention refers to a method for preparing laevomycetin ointment with glutaric aldehyde and ethonium on the basis of modified laevomycetin, consisting in the fact that laevomycetin 100 mg/ml detoxified and polymerised at first in glutaric aldehyde 0.1-0.2% at 38-40°C for 3-5 days, then in 0.2% ethonium at 38-40°C for 2-3 days, is used for preparing 1-3% Vaseline ointment. |
|
|
Cosmetic and pharmaceutical compositions of calixarene molecules Invention relates to pharmaceutical industry and represents application of calix[6]arene of formula (1A) or (1B) for treatment of skin contamination with uranium, plutonium or americium. |
|
Invention relates to compounds of general formula (I), where Y is selected from -CRay=CRby- and -CHRay-CRby=CRcy-; each Ray, Rby and Rcy is independently selected from a hydrogen atom and unsubstituted C1-C12 alkyl; each R1, R2, R3, R4 and R5 is independently selected from a hydrogen atom and unsubstituted C1-C12 alkyl; R6 is selected from NR8R9 and OR10; W is selected from NR7; R7 is a hydrogen atom; R8 is a hydrogen atom; R10 is an unsubstuted C2-C12 alkenyl; R9 is a substituted C2-C12 alkenyl which is substituted in one or more positions by a halogen , OR', OCONHR' and OH, protected by a silyl ether, where R' is hydrogen; each of R11, R12, R13, R14 and R15 is independently selected from a hydrogen atom, ORa, OSiRaRbRc; and each Ra, Rb and Rc is independently selected from a hydrogen atom and unsubstituted C1-C12 alkyl. The invention also relates to a pharmaceutical composition having cytotoxic activity, which contains said compounds, use of compounds of formula (I) to prepare a medicinal agent for treating cancer and methods of producing compounds of formula (I). |
|
Invention relates to novel compounds, represented by the following formula (I) and their pharmaceutically acceptable salts, where values for groups R1, R4-R6, Ra, m, n, Y, X are determined in the invention formula. Said compounds are used as preparations for enhancing growth of axons and prevention of diseases associated with histone diacetases, in particular tumours or diseases associated with cell proliferation. |
|
Method for increasing efficacy of laevomycetin (chloramphenicol) Invention refers to a method for increasing the efficacy of laevomycetin. This method consists in the fact that laevomycetin in the amount of 1 g in 8.0 ml of distilled water is detoxified and polymerised at first with 1.0 ml of 1% (0.15+0.05%) glutaric aldehyde at 38-40°C for 3-5 days, then added with 1.0 ml of 1% aethonium or 0.1% alkyldimethylbenzylammonium or 0.1% Biopag-D (polyhexamethylene hydrochloride) at 38-40°C for 3-5 days. |
|
|
Invention aims at a composition for treating pulmonary hypertension which contains an active agent consisting of 0.001 mg/ml to 20 mg/ml of an ACE inhibitor and additionally containing at least one humidifier. It is isotonic and has the pH value within 3 to 8. It is acceptable to administer the composition by inhalations into a mammal in need thereof. According to the invention, the compositions can represent a solution or a suspension, and preferentially, it is acceptable to administer them by spraying. The present invention also aims at a kit for treating a mammal suffering pulmonary hypertension. 2 primary claims, 12 secondary claims. |
|
|
Galena composition of aliskiren and hydrochlorothiazide Claimed invention relates to medicine and describes solid peroral drug form in form of pill, which includes: a) therapeutically effective quantity of aliskiren or its pharmaceutically acceptable salt, b) therapeutically effective quantity of hydrochlorothiazide (HCTA), and c) hydrophilic filler, which represents mixture of wheat starch and lactose. Method of obtaining solid pharmaceutical composition as well as its application are described. |
|
Compounds and methods for kinase modulation and indications for use of said compounds and methods Disclosed is a compound having chemical formula or a salt thereof, where: Ar is an optionally substituted heteroaryl; R1 in each case is independently selected from a group which includes halogen, lower alkyl, optionally substituted with one or more substitutes selected from fluorine, lower alkoxy, fluorine-substituted lower alkoxy, monoalkylamino, dialkylamino, -O-R5, -N(R5)-R6 and -N(R5)-C(X)-R7; m equals 0 or 1; n equals 0, 1 or 2; R2 is hydrogen or a halogen; L2 is -S(O)2-; R3 is a lower alkyl, optionally substituted with fluorine, C3-6 cycloalkyl, optionally substituted with a lower alkyl, a 5- or 6-member nitrogen-containing heterocycloalkyl, optionally substituted with one or more substitutes selected from fluorine, lower alkyl, fluorine-substituted lower alkyl, lower alkoxy, fluorine-substituted lower alkoxy, lower alkylthio or fluorine-substituted lower alkylthio, aryl, optionally substituted with a halogen, lower alkyl, optionally substituted with a halogen or lower alkoxy, optionally substituted with a halogen, or a heteroaryl, optionally substituted with a halogen or a lower alkyl; L1 is selected from a group which includes -O-, -C(R12R13)-X-, -X-C(R12R13)-, -C(R12R13)-N(R11)-, -(R11)-C(R12R13)-, -C(X)-N(R11)-, -N(R11)-C(X)-; X is O; R11 is hydrogen; R4 is hydrogen or a lower alkyl; R5 and R6 in each case are independently selected from a group which includes hydrogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, where each is optionally substituted with one or more substitutes selected from fluorine, lower alkoxy, fluorine-substituted lower alkoxy, lower alkylthio, fluorine-substituted lower alkylthio, monoalkylamino, dialkylamino; R7 in each case is independently selected from a group which includes lower alkyl; where the terms "lower alkyl", "lower alkoxy", "lower alkylthio", "monoalkylamino", "dialkylamino", "cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", are as described in the claim. The invention also discloses a pharmaceutical composition for treating Raf kinase mediated diseases which is based on a compound of formula I; use of the compound of formula I to produce a medicinal agent is also disclosed. |
|
Galenic formulations of aliskiren Claimed invention relates to medicine, namely to solid peroral dosage form, obtained by rotation pressing, which includes therapeutically effective quantity of aliskiren or its pharmaceutically acceptable salt, and active ingredient is present in said dosage form in amount higher than 38% by weight of peroral dosage form, as well as to method of obtaining said solid peroral dosage form. |
|
Treatment of oropharyngeal dysphagia Invention relates to perorally introduced product in form of viscosified drink, which is capable of stimulating swallowing reflex in an individual, containing thickening agent and at least one vanilloid receptor (VR-1) agonist, selected from group consisting of: capsiate, dihydrocapsaicine, nordihydrocapsaicine dihydrocapsiate, nordihydrocapsiate, homocapsaicine, homodihydro-capsaicine, vanillyl amyl n-nonanoic acid (VNA), anandomide, resiniferatoxin and olvanil. Product can also be liquid or with modified structure. Invention also relates to product application for prevention or treatment of oropharyngeal dysphagia in an individual. |
|
|
Obtaining and using phenylcyclobutylamide derivatives and stereoisomers thereof Invention relates to phenylcyclobutylamide derivatives of formula or a stereoisomer or pharmaceutically acceptable salt thereof. In formula (I), R is H, formacyl, acetyl, haloacetyl, benzoyl, benzyloxy carbonyl (Cbz), t-butoxy carbonyl (Boc), or 9-fluorenyl methoxyl carbonyl (Fmoc). The phenylcyclobutylamide derivative of formula (I), where R is H, is used to prepare medicine or a pharmaceutical composition for losing weight. The phenylcyclobutylamide derivatives of formula (I) are obtained by dissolving racemic or separate 1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine and R-protected racemic or D- or L-isoleucine with anhydrous tetrahydrofuran; a condensing agent is then added in droplets to the solution which is then stirred at room temperature overnight, the precipitate is filtered and washed with anhydrous diethyl ether several times. The filtrate and anhydrous diethyl ether eluate are collected; a crude product is the obtained by evaporation, separation and pufification by column chromatography to obtain a racemic or optical isomeric compound, 2-(R-amino)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-3-methylpentanamide; the R-protection group is removed to obtain a racemic or optical isomeric compound: 2-amino-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-3-methylpentanamide; a pharmaceutically acceptable acid is used to prepare a salt thereof. |
|
Invention refers to medicine, in particular to anesthesiology and intensive care, and may be used if preoperative preparation of the patients with chronic pancreatitis and manifested pain syndrome required. For this purpose, back skin of a sitting patient is treated within a puncture at the Th7-Th8 level. Then, an epidural space is punctured, and a puncture catheter needle is introduced therein, and the catheter is pushed forward in the cranial direction to a depth of 3 cm. The needle is removed, and the catheter is placed along the spine and is brought out to the subclavian region while strapped all over. Thereafter, a test dose of 2% lidocaine 3.0 ml is introduced. If observing no effects of spinal block, prolonged permanent introduction of 0.2% ropivacaine at rate 4-5 ml/hour 3 times a day. With underlying it, 30 minutes before a meal, fractional introduction of 0.75% ropivacaine 3.0 ml and 0.005% fentanyl 1.0 ml for 4-5 days is performed. |
|
|
Method of treating bronchopneumonia in calves Invention relates to field of veterinary. Method of treating bronchopneumonia in calves, includes intramuscular introduction of antibacterial medication, as antibacterial medication used is 30% floron solution in dose 1 ml per 20 kg of weight with 48-hour interval and additionally amino acid-vitamin complex "Bitam" is introduced intramuscularly in dose 3 ml per 10 kg of weight three times every second day. |
|
|
Method of prevention or treatment of intrauterine growth retardation syndrome Invention relates to medicine, namely to obstetrics and gynecology and can be used for prevention and treatment of intrauterine growth retardation syndrome. For this purpose medications are administered to pregnant women of risk group in terms of pregnancy, determined in accordance with the critical period of fetus development. At term of pregnancy, equal to 14-18 weeks, administered is natural micronised progesterone in dose 200 mg intravaginally 2 times per day in 30-day course, complex of polyunsaturated fatty acids of family omega-3 in 30-day course, dry water extract of fresh artichoke leaves in dose 2 tablets 3 times per day in 14-day course, levocarnitin in dose 8 drops 3 times per day in 30-day course, instenon 5.0 ml on 5% dextrose in dose 500 ml intravenously 10 injections every second day per course, deproteinised hemoderivate from calf blood with low-molecular peptides and derivates of nucleic acids 5.0 ml on 5% dextrose in dose 500 ml intravenously every second day 10 injections per course, combined polyvitamin complex with micro- and macro-elements and potassium iodide in dose 200 mg per day daily until fetus birth. After that, at pregnancy term 20-24 weeks and 30-34 weeks, respectively, administered is complex of polyunsaturated fatty acids of family omega-3 in 30-day course, levocarnitin in dose 8-10 drops 3 times per day in 14-day course, calcium nadroparin in dose 0.3 ml subcutaneously in 30-day course, dry water extract of fresh artichoke leaves in dose 2 tablets 3 times per day in 14-day course, instenon on 5% dextrose in dose 500 ml intravenously 10 injections every second day per course, deproteinised hemoderivate from calf blood with low-molecular peptides and derivates of nucleic acids 5.0 ml on 5% dextrose in dose 500 ml intravenously 10 injections every second day per course. |
|
|
Method of anesthetics in abdominal surgery after laparoscopic or video-assisted appendectomy After performing main stage of surgery, under visual control needle puncture is performed into retroperitoneum space of right iliac fossa perpendicularly to skin, 1 cm inward from anterior superior iliac spine. Needle is passed inward, downward and frontward to the depth 6-8 cm, sliding on internal surface of iliac bone. Conductor is introduced through needle lumen and polyethylene catheter, through which after the end of operation, after 4-6 and 10-12 hours introduced is naropin in dose 2.5 mg/ml in 0.9% sodium chloride solution, is installed. |
|
|
Crystalline forms of aliskiren hemifumarate Crystalline form of aliskiren hemifumarate is characterized by the picture of X-ray diffraction in powder demonstrating the following main peaks, given at degrees 2 Teta+/- 0.3 degree: 3.8, 6.5, 7.7, 8.0, 15.6 and 17.4. said form is obtained from solution with weight ratio (weight/weight) acetonyl : ethanol, being in the interval from 90:10 to 75:25 (for instance, 80:20) at suitable temperature in the interval from 15 to 40°C, for instance, by cooling from 37°C to 35°C and especially after dimming - by further cooling to 20°C, ensuring aliskiren hemifumarate crystallisation, filtered and dried under vacuum, for instance, at 10 mbar and 40°C. Crystalline form of aliskiren hemifumarate is applied for obtaining pharmaceutical composition, suitable for treating disease in warm-blooded animal, modulated by rennin inhibition. |
|
Compositions and method of treating cattle and pigs' infectious diseases Subcutaneous composition for treating microbial infection in an animal contains: a) fluorfenicol approx. 300 mg/ml; b) flunixin or one of its pharmaceutically acceptable salts approx. 16.5 mg/ml; and c) aprotonic polar solvent approx. 5 to approx. 80% specified in a group consisting of N,N-dimethylacetamide, N-methyl-2-pyrrolidone, 2-pyrrolidone, formal glycerol and their combination. A method of treating an animal's disease specified in a group consisting of cattle respiratory disease, pig's respiratory disease, coffin rot, acute mastitis, acute epidemic conjunctivitis, metritis and enteritis in an animal involving the stage of the subcutaneous introduction of a therapeutically effective amount of said composition into the animal requiring such treatment. |
|
Invention relates to medicine, namely to anesthesiology, and can be used in patients during and after highly traumatic operations on thoracic and lumbar spine. For this purpose general anesthesia is performed with sevoflurane. Additionally during operation epidural analgesia is performed by infusion of mixture of 0.2% solution of ropivacaine with fentanyl 2 mcg/ml and adrenalin 2 mcg/ml at rate 5-10 ml/hour. In postoperative period anesthesia is performed by constant infusion of mixture at rate 4-8 ml/hour. |
|
|
Invention relates to field of veterinary. Medicine for treatment and prevention of postnatal endometritis and syndrome of metritis-mastitis-agalactia in sows, contains the following components, wt %: Florfenicol - 1.0-3.0, lincomycin hydrochloride - 1.0-3.0, Dimethylsulfoxide - 10.0, Glycerin - 10.0, 1.2 propylene glycol - 10.0, Sunflower refined oil - 12.5, emulsion wax -1.0, stearic acid - 0.9, Water for injection - to 100%. |
|
|
Therapeutic agent for treating fibromyalgia Invention refers to pharmacology and represents an agent for fibromyalgia containing pilocarpine or pilocarpine hydrochloride, and a pharmaceutically acceptable carrier wherein a daily dose of pilocarpine or pilocarpine hydrochloride makes 0.1 mg to 1000 mg. |
|
(r)-arylalkylamino derivatives and pharmaceutical compositions containing them Present invention refers to certain (R)-arylalkylamino derivatives of formula , wherein R is specified in the following values: - 2-thiazolyl substituted by a trifluoromethyl group; -CORa, SO2Ra, wherein Ra is specified in the following values -C1-C5-alkyl, C3-C6- cycloalkyl, phenyl, a heteroaryl group specified in thiophen, furan and pyridine with heteroaryl being unsubstituted or substituted by a group specified in COOH and C1-C4-acyloxy; - ω-aminoalkylamino group of formula , wherein X represents: - linear or branched C1-C6 alkylene; R2 and R3 together with N atom bound therewith form a 3-7-member nitrogen-containing heterocyclic ring of formula , wherein Y represents a single bond; and p is equal to 0 or represents an integer 1 to 3; R1 represents linear or branched C1-C5 alkyl; Ar represents a phenyl group substituted by one or more groups independently specified in benzoyl, heteroarylcarbonyl wherein the heteroaryl group represents furan, 4'-trifluoromethane sulphonyloxy-, 4'-[1-methyl-1-(phenylsulphonyl)ethyl]- and 4'-benzole sulphonyloxy-. The compounds under the invention provides unexpectedly strong inhibiting action on C5a-induced chemotaxis of human PMN. |
|
Aliskiren and orotic acid salt Present invention refers to a new aliskiren and orotic acid salt, preparing and using it, pharmaceutical preparations containing said salt. The aliskiren and orotic acid salt is used to produce a drug preparation used for preventing and treating diseases or conditions which respond to treatment by renin inhibition. A method for preparing the aliskiren and orotic acid salt consists in the fact that (1) aliskiren in the form of a free base and orotic acid are dissolved in an organic solvent, (2) a solvent of the mixed solution is concentrated in heating, at low pressure if required, and slowly cooled to room temperature to boil out and precipitate, (3) the suspension is filtered and dried to prepare the salt. |
Another patent 2551097.